Novel treatments for gastrointestinal diseases and disorders

Phathom Pharmaceuticals is focused on transforming the treatment landscape for patients suffering from acid-related gastrointestinal (GI) disorders. The company is advancing its development programs, particularly in late-stage clinical trials, targeting conditions such as Non-Erosive Gastroesophageal Reflux Disease (NERD) and Eosinophilic Esophagitis (EoE). Their lead product, VOQUEZNA® (vonoprazan), is a potassium-competitive acid blocker (PCAB) that has been approved for multiple indications, including the healing of Erosive Esophagitis and the relief of heartburn associated with both Erosive and Non-Erosive GERD. This innovative therapeutic approach aims to address the unmet needs in the treatment of acid-related disorders, moving beyond traditional therapies.

The company is committed to a robust clinical research agenda, which includes various trial designs to evaluate the efficacy and safety of their investigational products. Phathom Pharmaceuticals emphasizes the importance of clinical trials as a means to provide access to new therapies, encouraging patient participation in these studies. Their focus on evolving the understanding and treatment of acid-related diseases is underscored by their dedication to improving patient outcomes and making effective therapies available as quickly and safely as possible.

United States

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. We have created a nimble, entrepreneurial environment that fosters the spirit of collective ownership, accountability, proprietorship and achievement — elements that are key to our success.

Digestive System Diseases

Phathom Pharmaceuticals

Bacterial infection

Phathom Pharmaceuticals is developing vonoprazan, a potassium-competitive acid blocker (P-CAB). P-CABs are a new class of medicines that block acid secretion in the stomach, and we are currently evaluating vonoprazan in the treatment of patients with gastroesophageal reflux disease (GERD), H. pylori infection, and other acid-related diseases.

VOQUEZNA (Vonoprazan) (Potassium competitive acid blocker)

Esophagitis

Gastroesophageal reflux disease

Intestinal infection

VOQUEZNA (Vonoprazan)(Potassium competitive acid blocker) 

Vonoprazan, is an oral small molecule potassium competitive acid blocker (P-CAB). P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. Phathom in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda, which completed 17 Phase 3 trials for vonorpazan and received marketing approval in Japan and eight other countries in Asia and Latin America.

Phathom Pharmaceuticals

Company Details